Campaigners emphasized that any advancement must stay affordable and accessible as the U.K. government on Friday launched a deal with the German company BioNTech to test new vaccinations for cancer and other diseases.
Cancer Vaccine Trials
In England, cancer patients will get early access to clinical trials incorporating tailored mRNA therapies, such as cancer vaccinations that are designed to activate the immune system to fight dangerous cells.
They will be given to individuals with early and late stages of the disease and will both kill active cancer cells and stop them from growing.
With a lab in Cambridge and a corporate office in London, BioNTech will establish new research and development centers in the U.K.
With a lab in Cambridge and a corporate office in London, BioNTech will establish new research and development centers in the U.K.
Together with American pharmaceutical giant Pfizer, the company created one of the most frequently used Covid-19 vaccines.
Its CEO, Ugur Sahin, claimed that the coronavirus pandemic had taught the company valuable lessons about the need for cooperation between the British National Health Service, academia, regulators, and the private sector in the creation of medicines, which it was now putting into practice.
“Our goal is to accelerate the development of immunotherapies and vaccines using technologies we have been researching for over 20 years,” he said in a statement. “The collaboration will cover various cancer types and infectious diseases affecting collectively hundreds of millions of people worldwide.”
According to Peter Johnson, the National Clinical Director for Cancer in Britain, mRNA technology has the potential to revolutionize how various illnesses are treated.
The news, the government told CNBC, represented a private investment in the United Kingdom, but it would be backed by a brand-new Cancer Vaccine Launch Pad supported by the NHS.
To read our blog on “After 2023, Gavi will discontinue the Covax vaccine-sharing program,” click here.
